Abbott Laboratories ABT
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.01B | 12.59B | 11.16B | 11.46B | 11.37B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.01B | 12.59B | 11.16B | 11.46B | 11.37B |
| Cost of Revenue | 5.63B | 5.33B | 4.89B | 4.91B | 5.08B |
| Gross Profit | 7.39B | 7.27B | 6.27B | 6.55B | 6.29B |
| SG&A Expenses | 4.11B | 3.87B | 3.58B | 2.93B | 2.90B |
| Depreciation & Amortization | 841.00M | 658.00M | 422.00M | 422.00M | 420.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 11.50B | 10.74B | 9.66B | 8.98B | 9.16B |
| Operating Income | 1.52B | 1.85B | 1.50B | 2.48B | 2.21B |
| Income Before Tax | 1.23B | 1.52B | 1.45B | 2.36B | 2.18B |
| Income Tax Expenses | 311.00M | 596.00M | 372.00M | 582.00M | 536.00M |
| Earnings from Continuing Operations | 920.00M | 928.00M | 1.08B | 1.78B | 1.64B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 920.00M | 928.00M | 1.08B | 1.78B | 1.64B |
| EBIT | 1.52B | 1.85B | 1.50B | 2.48B | 2.21B |
| EBITDA | 2.77B | 2.91B | 2.31B | 3.27B | 3.00B |
| EPS Basic | 0.53 | 0.53 | 0.62 | 1.00 | 0.94 |
| Normalized Basic EPS | 0.44 | 0.55 | 0.52 | 0.87 | 0.78 |
| EPS Diluted | 0.53 | 0.53 | 0.61 | 1.00 | 0.94 |
| Normalized Diluted EPS | 0.44 | 0.55 | 0.52 | 0.87 | 0.78 |
| Average Basic Shares Outstanding | 1.73B | 1.74B | 1.74B | 1.75B | 1.74B |
| Average Diluted Shares Outstanding | 1.74B | 1.74B | 1.75B | 1.75B | 1.75B |
| Dividend Per Share | 0.63 | 0.63 | 0.63 | 0.63 | 0.59 |
| Payout Ratio | 118.91% | 118.75% | 101.95% | 58.00% | 62.71% |